Best practices for the Multidisciplinary Management of NHL using Antibody Therapeutics
Podcast
Pre-test

Questions marked with a * are required
100%
Contact Information
Geoffrey is a 69-year-old man who you previously diagnosed as having stage IV non-GCB DLBCL with an IPI of 4. You administered three cycles of R-CHOP, noting slowly responsive disease on CT, whereupon you administered three more cycles of R-CHOP. Repeat biopsy, however, confirmed primary refractory disease. As second-line therapy, you then prescribed two cycles of polatuzumab vedotin and rituximab as bridging treatment for Geoffrey, followed by fludarabine/cyclophosphamide lymphodepletion and CD19-directed CAR T-cell treatment with axi-cel. Geoffrey continues to progress. What is the next best step for this patient? 
Which of the following statements best describes the findings of the phase 2 LOTIS-2 trial investigating loncastuximab tesirine in patients with R/R DLBCL? 
Powered by QuestionPro